Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Covid-19 in Pemphigus Vulgaris Patients With Previous Rituximab Therapy: A Tele-Medicine Experience Publisher Pubmed



Shahididadras M1 ; Abdollahimajd F1 ; Ohadi L1 ; Tabary M2 ; Araghi F1 ; Mozafari N1, 3 ; Toosi P1 ; Dadkhahfar S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Dermatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Journal of Dermatological Treatment Published:2020


Abstract

[No abstract available]
Related Docs
1. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
2. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)
3. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)
4. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
5. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
6. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
7. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (7)
Hamid Reza Mahmoodi (6)